Soligenix is enrolling patients in its FLASH2 study, with a formal interim analysis anticipated early in 2026. <li /> SNGX's HyBryte is a ...

Pembrolizumab shows clinical promise as a treatment for mycosis fungoides and Sézary syndrome, achieving a response in nearly ...

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company specializing in the development and commercialization of treatments for rare diseases and unmet medical needs, is making significant ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Equities researchers at Zacks Small Cap issued their Q1 2025 earnings per share estimates for Soligenix in a research report ...

Q4 2024 Earnings Call Transcript March 27, 2025 Innate Pharma S.A. misses on earnings expectations. Reported EPS is $-0.33474 ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...

Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science ...

A new article outlines a new tool that measures blood inflammation as a marker for poor CAR T therapy outcomes.

A research team led by Prof. Gu Hongcang from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences has ...

Researchers with City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United ...

A review of the side effects of CAR T-cell therapy, including CRS, ICANS, tumor lysis syndrome, and late-onset toxicities, and management strategies.